The recommendations listed in this document are, whenever possible, evidence based. An
extensive review was conducted on literature published through March 1, 2020. Searches …

Aim This executive summary of the valvular heart disease guideline provides
recommendations for clinicians to diagnose and manage valvular heart disease as well as …

Cardiovascular (CV) disease complicates an estimated 1% to 4% of all pregnancies and is
the leading cause of death in pregnant and postpartum women in the United States. 1, 2 …

Pregnancy is a hemostatic challenge: women are prone to thromboembolism during their
pregnancy and at the same time, especially during delivery, there is substantial risk of …

Aim This executive summary of the valvular heart disease guideline provides
recommendations for clinicians to diagnose and manage valvular heart disease as well as …

The growing population of women with heart disease of reproductive age has been
associated with an increasing number of high-risk pregnancies. Pregnant women with heart …

Management strategies for patients with atrial fibrillation (AF) in association with valvular
heart disease (VHD) have been less informed by randomized trials, which have largely …

Cardiac disease remains a major cause of morbidity and mortality in pregnant and post-
partum women, although progress has been made, with specialist joint obstetric–cardiology …

Introduction Randomized controlled trials have shown that direct oral anticoagulants
(DOACs) are a safe and effective alternative to vitamin K antagonists (VKAs) for the …

Maternal ischemic stroke and cerebral venous sinus thrombosis (CVST) are dreaded
complications of pregnancy and major contributors to maternal disability and mortality. This …